Literature DB >> 7698839

The epidemiology of hepatitis C in Turkey.

D L Thomas1, R W Mahley, S Badur, E Palaoglu, T C Quinn.   

Abstract

Hepatitis C virus (HCV) and hepatitis E virus (HEV) are the principal causes of non-A, non-B hepatitis worldwide, and in Turkey one-third of the cases of acute hepatitis are non-A, non-B. To explore the epidemiology of HCV in Turkey (including the association of HCV with HEV), a seroprevalence study of HCV was conducted. Sera from residents from five distinct regions of the country were tested for antibodies to HCV (anti-HCV) and HEV (anti-HEV). Anti-HCV was detected in 21 (1.5%) of 1,374 persons and was more common in residents over 54 years of age (p = 0.02), with less than primary education (p = 0.013), more than two children (p = 0.003), and who lived in the regions of Ayvalik (p = 0.046) or Trabzon (p = 0.038) compared to Istanbul. Anti-HCV was marginally associated with anti-HEV, which was found in 5.9% of residents. However, this association was lost after controlling for age and education (p = 0.225). HCV infection occurs in all regions of Turkey and is more common in persons who are older and of low socioeconomic status. As resources permit, efforts to reduce the transmission of HCV in Turkey (such as screening blood donations for anti-HCV) are indicated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7698839     DOI: 10.1007/bf01715499

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  14 in total

1.  Prevalence of antibodies to hepatitis C virus in blood donors and risk groups in Istanbul, Turkey.

Authors:  O S Yenen; S Badur
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

2.  Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1991-04-19

3.  Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland.

Authors:  J G Donahue; K E Nelson; A Muñoz; D Vlahov; L L Rennie; E L Taylor; A J Saah; S Cohn; N J Odaka; H Farzadegan
Journal:  Am J Epidemiol       Date:  1991-11-15       Impact factor: 4.897

4.  Epidemiology of hepatitis E virus infection in Turkey.

Authors:  D L Thomas; R W Mahley; S Badur; K E Palaoglu; T C Quinn
Journal:  Lancet       Date:  1993-06-19       Impact factor: 79.321

5.  Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.

Authors:  H J Alter; R H Purcell; J W Shih; J C Melpolder; M Houghton; Q L Choo; G Kuo
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

6.  The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team.

Authors:  M J Alter; H S Margolis; K Krawczynski; F N Judson; A Mares; W J Alexander; P Y Hu; J K Miller; M A Gerber; R E Sampliner
Journal:  N Engl J Med       Date:  1992-12-31       Impact factor: 91.245

7.  The declining risk of post-transfusion hepatitis C virus infection.

Authors:  J G Donahue; A Muñoz; P M Ness; D E Brown; D H Yawn; H A McAllister; B A Reitz; K E Nelson
Journal:  N Engl J Med       Date:  1992-08-06       Impact factor: 91.245

8.  Hepatitis C virus infection among patients attending a clinic for sexually transmitted diseases.

Authors:  H S Weinstock; G Bolan; A L Reingold; L B Polish
Journal:  JAMA       Date:  1993-01-20       Impact factor: 56.272

9.  Hepatitis C virus antibodies among risk groups in Turkey.

Authors:  I Köksal; K Biberoğlu; S Biberoğlu; F Koç; Y Ayma; F Aker; H Köksal
Journal:  Infection       Date:  1991 Jul-Aug       Impact factor: 3.553

10.  Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route.

Authors:  M S Balayan; A G Andjaparidze; S S Savinskaya; E S Ketiladze; D M Braginsky; A P Savinov; V F Poleschuk
Journal:  Intervirology       Date:  1983       Impact factor: 1.763

View more
  8 in total

Review 1.  Mode of hepatitis C virus infection, epidemiology, and chronicity rate in the general population and risk groups.

Authors:  H L Tillmann; M P Manns
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

2.  Risk factors for hepatocellular carcinoma in Turkey.

Authors:  O Uzunalimoğlu; C Yurdaydin; H Cetinkaya; H Bozkaya; T Sahin; S Colakoğlu; E Tankurt; M Sarioğlu; S Ozenirler; H Akkiz; N Tözün; H Değertekin; A Okten
Journal:  Dig Dis Sci       Date:  2001-05       Impact factor: 3.199

3.  Detection of mutant p53 in hepatocellular cancer from Turkey and its correlation with clinicopathologic parameters.

Authors:  Cem Cengiz; Ulus S Akarca; Erdem Goker; Gul Yuce
Journal:  Dig Dis Sci       Date:  2003-05       Impact factor: 3.199

4.  Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey.

Authors:  Necati Örmeci; Simten Malhan; İsmail Balık; Gül Ergör; Homie Razavi; Sarah Robbins
Journal:  Hepatol Int       Date:  2017-10-12       Impact factor: 6.047

Review 5.  Estimation of Cancer Burden Attributable to Infection in Asia.

Authors:  He Huang; Xiao-Feng Hu; Fang-Hui Zhao; Suzanne M Garland; Neerja Bhatla; You-Lin Qiao
Journal:  J Epidemiol       Date:  2015-09-19       Impact factor: 3.211

Review 6.  Light and Darkness: Prevalence of Hepatitis E Virus Infection among the General Population.

Authors:  José-Manuel Echevarría
Journal:  Scientifica (Cairo)       Date:  2014-02-10

7.  HBsAg, Anti-HCV and Anti-HIV Seroprevalance Among Drug Users: a Retrospective Assessment.

Authors:  Imre Altuğlu; Selin Tanyeri; Ayşın Zeytinoğlu; Ayşe Ender Altintoprak
Journal:  Noro Psikiyatr Ars       Date:  2019-07-16       Impact factor: 1.339

8.  Primary care physicians' approach to diagnosis and treatment of hepatitis B and hepatitis C patients.

Authors:  Yildiz Peksen; Sevgi Canbaz; Hakan Leblebicioglu; Mustafa Sunbul; Saban Esen; Ahmet Tevfik Sunter
Journal:  BMC Gastroenterol       Date:  2004-02-06       Impact factor: 3.067

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.